Hepatocellular carcinoma progression is protected by miRNA-34c-5p by regulating FAM83A
To elucidate the role of microRNA-34c-5p (miRNA-34c-5p) in the progression of hepatocellular carcinoma (HCC) and the indicated mechanism. Relative levels of miRNA-34c-5p and FAM83A in HCC tissues and cell lines were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Their influe...
Saved in:
Published in | European review for medical and pharmacological sciences Vol. 24; no. 11; p. 6046 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Italy
01.06.2020
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | To elucidate the role of microRNA-34c-5p (miRNA-34c-5p) in the progression of hepatocellular carcinoma (HCC) and the indicated mechanism.
Relative levels of miRNA-34c-5p and FAM83A in HCC tissues and cell lines were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Their influences on clinical features in HCC patients were analyzed. Kaplan-Meier method was introduced for assessing the relationship between miRNA-34c-5p and overall survival in HCC. After overexpression of miRNA-34c-5p in HepG2 and HB611 cells, we detected proliferative, migratory and invasive abilities by cell counting kit-8 (CCK-8) and transwell assay. The interaction between miRNA-34c-5p and FAM83A was explored by Dual-Luciferase reporter assay. Finally, their co-regulation on HCC cell phenotypes was examined.
MiRNA-34c-5p was downregulated in HCC tissues, especially stage III+IV cases. Its level was correlated to tumor size, tumor number and TNM staging in HCC. Overexpression of miRNA-34c-5p inhibited proliferative, migratory and invasive abilities in HepG2 and HB611 cells. In addition, miRNA-34c-5p targeted on FAM83A and negatively regulated its level. Overexpression of FAM83A could reverse the inhibitory effects of miRNA-34c-5p on malignant phenotypes of HCC cells.
By negatively regulating FAM83A level, miRNA-34c-5p alleviates the progression of HCC. |
---|---|
AbstractList | To elucidate the role of microRNA-34c-5p (miRNA-34c-5p) in the progression of hepatocellular carcinoma (HCC) and the indicated mechanism.
Relative levels of miRNA-34c-5p and FAM83A in HCC tissues and cell lines were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Their influences on clinical features in HCC patients were analyzed. Kaplan-Meier method was introduced for assessing the relationship between miRNA-34c-5p and overall survival in HCC. After overexpression of miRNA-34c-5p in HepG2 and HB611 cells, we detected proliferative, migratory and invasive abilities by cell counting kit-8 (CCK-8) and transwell assay. The interaction between miRNA-34c-5p and FAM83A was explored by Dual-Luciferase reporter assay. Finally, their co-regulation on HCC cell phenotypes was examined.
MiRNA-34c-5p was downregulated in HCC tissues, especially stage III+IV cases. Its level was correlated to tumor size, tumor number and TNM staging in HCC. Overexpression of miRNA-34c-5p inhibited proliferative, migratory and invasive abilities in HepG2 and HB611 cells. In addition, miRNA-34c-5p targeted on FAM83A and negatively regulated its level. Overexpression of FAM83A could reverse the inhibitory effects of miRNA-34c-5p on malignant phenotypes of HCC cells.
By negatively regulating FAM83A level, miRNA-34c-5p alleviates the progression of HCC. |
Author | Yu, W-S Lin, Z-Q Lu, C-L Guo, R-P Ye, Z-W Wang, Z-G |
Author_xml | – sequence: 1 givenname: W-S surname: Yu fullname: Yu, W-S email: Luchunli1998@163.com organization: Department of General Surgery, Dongguan People's Hospital, Southern Medical University, Dongguan, China. Luchunli1998@163.com – sequence: 2 givenname: Z-G surname: Wang fullname: Wang, Z-G – sequence: 3 givenname: R-P surname: Guo fullname: Guo, R-P – sequence: 4 givenname: Z-Q surname: Lin fullname: Lin, Z-Q – sequence: 5 givenname: Z-W surname: Ye fullname: Ye, Z-W – sequence: 6 givenname: C-L surname: Lu fullname: Lu, C-L |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32572919$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j9tKxDAYhIMouq6-gUheoJr8OTS9LIu7K6wKot6WNPlbCj2EtBX27e2iXs18AzMw1-S8H3ok5I6zB9BCqUecY8TvAhgwpgvgMsvOyArAyISlkF2SKwFqMTxbka89BjsNDtt2bm2kzkbX9ENnaYhDHXEcm6GnzXjCCd2EnpZH2jXvr3kipEtUOHHEemlPTV_Tbf5iRH5DLirbjnj7p2vyuX362OyTw9vueZMfkgCcTwkC86WVwhihlZGGgVNW-oxp6bhFKe2SgNLAFTqvS8-5rNKUpVpXmWAC1uT-dzfMZYe-CLHpbDwW_wfhB7szUGs |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.26355/eurrev_202006_21499 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
EISSN | 2284-0729 |
ExternalDocumentID | 32572919 |
Genre | Journal Article |
GroupedDBID | CGR CUY CVF ECM EIF NPM |
ID | FETCH-LOGICAL-p211t-e20dba438836584802c5a4d9064c1ae44a02c256215ecd6bd114f770766f93032 |
IngestDate | Thu Jan 02 22:56:06 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p211t-e20dba438836584802c5a4d9064c1ae44a02c256215ecd6bd114f770766f93032 |
PMID | 32572919 |
ParticipantIDs | pubmed_primary_32572919 |
PublicationCentury | 2000 |
PublicationDate | 2020-06-01 |
PublicationDateYYYYMMDD | 2020-06-01 |
PublicationDate_xml | – month: 06 year: 2020 text: 2020-06-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Italy |
PublicationPlace_xml | – name: Italy |
PublicationTitle | European review for medical and pharmacological sciences |
PublicationTitleAlternate | Eur Rev Med Pharmacol Sci |
PublicationYear | 2020 |
Score | 2.2741883 |
Snippet | To elucidate the role of microRNA-34c-5p (miRNA-34c-5p) in the progression of hepatocellular carcinoma (HCC) and the indicated mechanism.
Relative levels of... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 6046 |
SubjectTerms | Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - pathology Cells, Cultured Disease Progression Female Humans Liver Neoplasms - metabolism Liver Neoplasms - pathology Male MicroRNAs - genetics MicroRNAs - metabolism Middle Aged Neoplasm Proteins - genetics Neoplasm Proteins - metabolism |
Title | Hepatocellular carcinoma progression is protected by miRNA-34c-5p by regulating FAM83A |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32572919 |
Volume | 24 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwELUKSIgLArFv8oGrS-rYWY4VolRIraBiKb1UtuNIHLoIWiT4A_6asZ0moSpS4RIldjZlXiYzk5k3CJ1HXEmfKkHiJOCEMcGIEIwToaJUB4aQxbbzabWD5gO76fJupfJVylqaTmRVfS6sK_mPVGEM5GqqZP8g2fykMADrIF9YgoRhuZSMm_AtmYxM7N0mkyrTF2g4GgiXdeUYN0zH8oyMwRmbg5dOu058pggfm-1X143ehAwa9Vbk1xcG67MSF5OUOMj-7ViKgYL5uqivVEVe4vPUJvGR3OR8yuLTPZI39bqe2nBthxSNlB2xQY_clYMS1CuSp6raKi8Knz1iWMnLmtZVS88QVSvpzcBzgch5hW6ocgz5hTZkVe99cykv6FNw6-Ly7iCW8cAK2QcVROPaErNzNNuzqRW0Ag6H6aB623KllvYeLhbcwQZanx0155RY4-R-C21mXgWuO4hso4oe7qDHn_DAOTxwCR745Q3n8MDyA5fhYbYLeGAHj1300Li6v2ySrI0GGYN3PyGaeokUzI8i35ibkUcVFyyJwRhVNaHh_YQRsHzB-NMqCWQCLnIahl4YBGkMFg7dQ6vD0VAfICyk4JqLJJIqBWXPZBgLpsLE5z6jScwP0b57DP2x40rpzx7Q0a8zx2ijQNAJWkvh5dSnYOlN5JmVwjeh-1Ls |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hepatocellular+carcinoma+progression+is+protected+by+miRNA-34c-5p+by+regulating+FAM83A&rft.jtitle=European+review+for+medical+and+pharmacological+sciences&rft.au=Yu%2C+W-S&rft.au=Wang%2C+Z-G&rft.au=Guo%2C+R-P&rft.au=Lin%2C+Z-Q&rft.date=2020-06-01&rft.eissn=2284-0729&rft.volume=24&rft.issue=11&rft.spage=6046&rft_id=info:doi/10.26355%2Feurrev_202006_21499&rft_id=info%3Apmid%2F32572919&rft_id=info%3Apmid%2F32572919&rft.externalDocID=32572919 |